The Effect of Losartan in Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer: A Randomized, Controlled Study - PubMed
3 days ago
- #breast cancer
- #losartan
- #neuropathy
- Losartan significantly reduces the incidence of grade 2 or higher paclitaxel-induced peripheral neuropathy (PIPN) in breast cancer patients (33.3% vs. 86.4%, p < 0.001).
- Losartan delays the onset of neuropathy (73.27 vs. 43.75 days; HR = 0.2, 95% CI: 0.11-0.35) compared to standard care alone.
- Patients treated with losartan reported superior quality of life (FACT/GOG-NTX: 31.87 ± 6.43 vs. 15.45 ± 10.04; p < 0.001) and reduced pain scores (Median VAS 3 vs. 8; p < 0.001).
- Serum nerve growth factor (NGF) levels were comparable between groups, and adverse events were similar.
- Losartan shows promise as a low-cost PIPN prophylactic without additional toxicity, warranting further validation in larger trials.